메뉴 건너뛰기
The Lancet Respiratory Medicine
Volumn 2, Issue 6, 2014, Pages 432-434
Prevention of invasive pneumococcal disease: New evidence

(1)  Rodgers, Gail a  

a NONE   (United States)
Author keywords

[No Author keywords available]
Indexed keywords

PNEUMOCOCCUS VACCINE; 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE;
EID: 84901825580     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70076-1     Document Type: Note
Times cited : (2)
References (10)
  • 1
    • 84901848686 scopus 로고    scopus 로고
    • WHO. Recommendations for the production and control of pneumococcal conjugate vaccines. 2005. WHO Technical Report Series. Number 927.
    • WHO. Recommendations for the production and control of pneumococcal conjugate vaccines. 2005. WHO Technical Report Series. Number 927.
  • 2
    • 84901754792 scopus 로고    scopus 로고
    • Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study
    • the Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group, published online April 10.
    • Domingues CMAS, Verani JR, Montenegro Renoiner EI, et al. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2014, the Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group, published online April 10. http://dx.doi.org/10.1016/S2213-2600(14)70060-8.
    • (2014) Lancet Respir Med
    • Domingues, C.M.A.S.1    Verani, J.R.2    Montenegro Renoiner, E.I.3
  • 3
    • 79959770706 scopus 로고    scopus 로고
    • Hospitalization rates for pneumococcal disease in Brazil, 2004-2006
    • Novaes HMD, Sartori AMC, Soárez PC Hospitalization rates for pneumococcal disease in Brazil, 2004-2006. Rev Saude Publica 2011, 45:539-547.
    • (2011) Rev Saude Publica , vol.45 , pp. 539-547
    • Novaes, H.M.D.1    Sartori, A.M.C.2    Soárez, P.C.3
  • 4
    • 81355147126 scopus 로고    scopus 로고
    • Clinical outcome of pneumococcal meningitis during the emergence of penicillin-resistant Streptococcus pneumoniae: an observational study
    • Gouveira ED, Reis JN, Flannery B, et al. Clinical outcome of pneumococcal meningitis during the emergence of penicillin-resistant Streptococcus pneumoniae: an observational study. BMC Infect Dis 2011, 11:323.
    • (2011) BMC Infect Dis , vol.11 , pp. 323
    • Gouveira, E.D.1    Reis, J.N.2    Flannery, B.3
  • 5
    • 33750346251 scopus 로고    scopus 로고
    • Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study
    • Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.
    • (2006) Lancet , vol.368 , pp. 1495-1502
    • Whitney, C.G.1    Pilishvili, T.2    Farley, M.M.3
  • 6
    • 85099173020 scopus 로고    scopus 로고
    • Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial
    • Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013, 381:214-222.
    • (2013) Lancet , vol.381 , pp. 214-222
    • Palmu, A.A.1    Jokinen, J.2    Borys, D.3
  • 7
    • 65549115895 scopus 로고    scopus 로고
    • Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine
    • Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009, 28(4 suppl):S66-S76.
    • (2009) Pediatr Infect Dis J , vol.28 , Issue.4 SUPPL.
    • Vesikari, T.1    Wysocki, J.2    Chevallier, B.3
  • 8
    • 84876216991 scopus 로고    scopus 로고
    • Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine
    • Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013, 32:203-207.
    • (2013) Pediatr Infect Dis J , vol.32 , pp. 203-207
    • Kaplan, S.L.1    Barson, W.J.2    Lin, P.L.3
  • 9
    • 82555187917 scopus 로고    scopus 로고
    • Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
    • Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011, 29:9127-9131.
    • (2011) Vaccine , vol.29 , pp. 9127-9131
    • Miller, E.1    Andrews, N.J.2    Waight, P.A.3
  • 10
    • 77956295617 scopus 로고    scopus 로고
    • Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers
    • Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010, 126:e493-e505.
    • (2010) Pediatrics , vol.126
    • Yeh, S.H.1    Gurtman, A.2    Hurley, D.C.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.